Komori
Share Issuance and Disposal4593HEALIOS K.K.Pharmaceuticals

Notice Regarding the Finalization of the Terms of the Paid Stock Options (29th Series Stock Acquisition Rights)

The previously undecided issuance details, including the eligible allottees and the number of rights allotted, have been finalized for the Series 29 Stock Acquisition Rights approved on 17 June 2026. A total of 121,356 rights will be allotted to 52 people, representing 12,135,600 common shares obtainable in the future.

Worth reading
42Recurring
Scored from 3 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
12135600
Shares
Wording
Definitive
How definitive the wording is.

Details of issuance or disposal

Issuance of paid stock options (Series 29 stock acquisition rights)

Who receives how much

12,135,600 common shares (121,356 Stock Acquisition Rights)

Directors of the company3 / 1,500
The Company's executive officers, including directors serving concurrently as executive officers4 / 103,880 rights
The Company's employees43 / 8,976 rights
Directors of the company's subsidiaries1 / 500 rights
Employees of the company's subsidiaries1 / 6,500 rights

The height of each bar represents the proportion of shares received by each allottee. The thin line below represents the number of existing shares to which these shares are added.

Terms of the stock acquisition rights
Number of Stock Acquisition Rights
Total number issued: 121,356 rights; outstanding unexercised rights: Not disclosed
Categories and Number of Persons Covered
The Company's directors: 3 people, 1,500 rights; the Company's executive officers, including directors who concurrently serve as executive officers: 4 people, 103,880 rights; the Company's employees: 43 people, 8,976 rights; directors of the Company's subsidiaries: 1 person, 500 rights; employees of the Company's subsidiaries: 1 person, 6,500 rights
Details of issuance or disposal
ItemDetails
Type of issuance or disposalIssuance of paid stock options (Series 29 stock acquisition rights)
Number of shares to be issued or disposed of12,135,600 common shares (121,356 Stock Acquisition Rights)
Intended allotteeName Directors of the company / Number of Employees 3 / Number of Shares 1,500, Name The Company's executive officers, including directors serving concurrently as executive officers / Number of Employees 4 / Number of Shares 103,880 rights, Name The Company's employees / Number of Employees 43 / Number of Shares 8,976 rights, Name Directors of the company's subsidiaries / Number of Employees 1 / Number of Shares 500 rights, Name Employees of the company's subsidiaries / Number of Employees 1 / Number of Shares 6,500 rights
Number of Stock Acquisition RightsTotal number issued: 121,356 rights; outstanding unexercised rights: Not disclosed
Categories and Number of Persons CoveredThe Company's directors: 3 people, 1,500 rights; the Company's executive officers, including directors who concurrently serve as executive officers: 4 people, 103,880 rights; the Company's employees: 43 people, 8,976 rights; directors of the Company's subsidiaries: 1 person, 500 rights; employees of the Company's subsidiaries: 1 person, 6,500 rights
Items this document does not state (23)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allottee's holding policyDilution RateTotal number of issued sharesBasis for determining the amount to be paidExercise priceExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioProcedures under the Corporate Code of ConductMost recent equity financingMajor shareholders after the offeringImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Because the previously undecided matters among the issuance details have been finalized based on a resolution of the Board of Directors held on 17 June 2026.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding the Finalization of the Terms of the Paid Stock Options (29th Series Stock Acquisition Rights) | HEALIOS K.K. (4593) timely disclosure | Komori